Brand Names of Meropenem in Kenya
Bestinem®, Sun Pharmaceutical Industries Limited
Inno-Mero®, Innocia Lifesciences Pvt. Ltd.
Monan® , M.J. Biopharm Pvt. Limited
Merogram® , Auronext Pharma. Pvt. Ltd
Meromark®, Marksans Pharma Limited
Meropen®, Renata Limited
Meronem®, Pfizer Laboratories Limited
Meropenem, Pharmathen Pharmaceuticals Ltd
Meronia®, Dafra Pharma GmbH
Merrobe® , Glenmark Pharmaceuticals Limited
Mepran®, Kopran Limited
Penem®, Theon Pharmaceuticals Ltd
Merosan®,PT Sanbe Farma
Ronem®, Venus Remedies Limited
Specbac®, Square Pharmaceuticals Ltd.
Zaxter®, Alkem Alkem Laboratories
MEROPENEM MODE OF ACTION
Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).
Meronem is indicated for the treatment of the following infections in adults and children aged 3 months and older
- Severe pneumonia, including hospital and ventilator-associated pneumonia.
- Broncho-pulmonary infections in cystic fibrosis
- Complicated urinary tract infections
- Complicated intra-abdominal infections
- Intra- and post-partum infections
- Complicated skin and soft tissue infections
- Acute bacterial meningitis Acute bacterial meningitis
Meronem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
DOSAGE AND ADMINISTRATION
500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa, a dose of 1 gram every 8 hours is recommended.
1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients.
1 gram every 8 hours by intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes for adult patients.
Dosage should be reduced in adult patients with renal impairment.
Hypersensitivity to the active substance or to any of the excipients .
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).
WARNINGS AND PRECAUTIONS
- Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams.
- Severe cutaneous adverse reactions have been reported in patients receiving Meropenem for injection (I.V.)
- Seizures and other adverse CNS experiences have been reported during treatment.
- Co-administration of Meropenem for injection (I.V.) with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures.
- Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported. Evaluate if diarrhea occurs.
- In patients with renal dysfunction, thrombocytopenia has been observed.
- Co-administration of Meropenem for injection (I.V.) with probenecid inhibits renal excretion of meropenem and is therefore not recommended.
- The concomitant use of Meropenem for injection (I.V.) and valproic acid or divalproex sodium is generally not recommended. Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.
Most common adverse reactions (2% or less) are: headache, nausea, constipation, diarrhea, anemia, vomiting, and rash
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, firstname.lastname@example.org or clicking below button:
Meropenem in Kenya
Meropenem in Kenya
Meropenem Price in Kenya
Meropenem Price in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: Intravenous
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: 1 hour
Legal Status | Dosage forms & Strengths
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
500mg | 1gm vials
|CompTox Dashboard (EPA)|
- PPB Drugs Retention Register
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization.
- Wiseman, Lynda R., et al. “Meropenem.” Drugs 50.1 (1995): 73-101.
- Mouton, Johan W., and John N. van den Anker. “Meropenem clinical pharmacokinetics.” Clinical pharmacokinetics 28.4 (1995): 275-286.
- Linden, Peter. “Safety profile of meropenem.” Drug safety 30.8 (2007): 657-668.